Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RO7122290 |
Trade Name | |
Synonyms | RO 7122290|RO-7122290 |
Drug Descriptions |
RO7122290 is a fusion protein consisting of a ligand of TNFRS9 fused to a Fab fragment targeting FAP, which may lead to activation of anti-tumor immune response against FAP-expressing tumor cells (Ann Oncol Sep 2020, 31 (Suppl 4), S707). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C175490 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + RO7122290 | Atezolizumab RO7122290 | 0 | 0 |
Obinutuzumab + RO6958688 + RO7122290 | Obinutuzumab RO6958688 RO7122290 | 0 | 1 |
RO7122290 | RO7122290 | 0 | 0 |